Petrarca Antonio, Rigacci Luigi, Monti Monica, Giannini Carlo, Bernardi Franco, Caini Patrizio, Colagrande Stefano, Bosi Alberto, Laffi Giacomo, Zignego Anna Linda
Department of Internal Medicine, Center for the Study of Systemic Manifestations of Hepatitis Viruses (MASVE), University of Florence, Florence, Italy.
Dig Liver Dis. 2007 Sep;39 Suppl 1:S129-33. doi: 10.1016/s1590-8658(07)80025-9.
Mixed cryoglobulinemia (MC) is the most strictly virus-related extrahepatic HCV disease. Antiviral therapy is considered the first therapeutic option; however, MC patients are frequently excluded from treatment due to contraindications. The effectiveness of B-cell depletion by anti-CD20 monoclonal antibody (rituximab) has recently been described, but the possibility of an immunodepression- related increase in viral replication and aminotransferase values limits its use in patients with advanced liver disease. Unfortunately, MC patients frequently also have cirrhosis. To our knowledge, no data are available regarding the effect of rituximab therapy in patients with decompensated cirrhosis. We report the successful treatment with rituximab (4 weekly infusions of 375 mg/m 2) of two patients (a 58-year-old man, and a 65-year-old woman) with HCV-related MC syndrome and decompensated liver cirrhosis. These patients underwent at least 6 months of post-treatment follow-up. In both cases a consistent improvement of MC syndrome was evident after treatment. In addition, improvement of liver protidosynthetic activity, increased prothrombin time, impressive reduction or disappearance of ascites and encephalopathy were also observed, in spite of some increase in viral titers or in ALT values. The Child-Pugh score improved from B8 to A6 and from Cll to B7, respectively. Pre- and post-treatment transjugular liver biopsies were available in 1 patient, showing disappearance of lymphocytic infiltration after treatment. These case reports show the effectiveness and safety of rituximab in patients with HCV-related MC and advanced cirrhosis, and strongly suggest that the depletion of CD20+ B-cells induced by rituximab treatment may be responsible for liver function improvement. The mechanisms involved are unknown. Interesting working hypotheses may implicate a role played by B-cell infiltrates in conditioning liver damage. The improvement of Kupffer cell function due to the cryocrit value reduction might also play a role.
混合性冷球蛋白血症(MC)是与病毒关联最为紧密的肝外丙型肝炎病毒(HCV)疾病。抗病毒治疗被视为首要治疗选择;然而,MC患者常因存在禁忌证而被排除在治疗之外。近期已有关于抗CD20单克隆抗体(利妥昔单抗)耗竭B细胞有效性的描述,但免疫抑制相关的病毒复制增加及转氨酶值升高限制了其在晚期肝病患者中的应用。不幸的是,MC患者常常也伴有肝硬化。据我们所知,尚无关于利妥昔单抗治疗失代偿期肝硬化患者疗效的数据。我们报告了两例(一名58岁男性和一名65岁女性)患有HCV相关MC综合征及失代偿期肝硬化的患者接受利妥昔单抗(每周1次,共4次,每次375 mg/m²)治疗成功的案例。这些患者接受了至少6个月的治疗后随访。在这两例患者中,治疗后MC综合征均有明显改善。此外,尽管病毒载量或丙氨酸氨基转移酶(ALT)值有所升高,但仍观察到肝脏蛋白质合成活性改善、凝血酶原时间延长、腹水和肝性脑病显著减轻或消失。Child-Pugh评分分别从B8改善至A6以及从C11改善至B7。1例患者可获取治疗前后的经颈静脉肝活检标本,显示治疗后淋巴细胞浸润消失。这些病例报告表明利妥昔单抗治疗HCV相关MC及晚期肝硬化患者有效且安全,并强烈提示利妥昔单抗治疗诱导的CD20⁺B细胞耗竭可能是肝功能改善的原因。其中涉及的机制尚不清楚。有趣的工作假说可能涉及B细胞浸润在调节肝损伤中所起的作用。由于冷球蛋白血症值降低导致库普弗细胞功能改善也可能发挥了作用。